Drug intelligence / Profile preview

ANN-103

Development stage: Preclinical
Lead developer: Anodyne Therapy
Modality: Peptides
Administration: Transdermal

Overview

**ANN-103** is a preclinical fixed-dose transdermal microneedle patch being developed by Anodyne Nanotech for **sarcopenic obesity**. The product combines an undisclosed glucagon-like peptide 1 receptor agonist with an undisclosed apelin receptor agonist to promote fat loss while preserving skeletal-muscle mass. It uses the HeroPatch microneedle platform for needle-free, tunable transdermal delivery of peptide biologics and is in PK/PD optimization.

Targets

GLP1R (GLP-1R)APLNR (Apelin receptor)

Beyond the preview

Go deeper on ANN-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANN-103.

Explore the full profile